Overview

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67>10% compared to historical control.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Pfizer

Treatments:

Anastrozole
Estrogens
Goserelin
Palbociclib